Tongqing Li
Associate Research Scientist in PharmacologyCards
About
Research
Publications
2023
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
Bergaggio E, Tai W, Aroldi A, Mecca C, Landoni E, Nüesch M, Mota I, Metovic J, Molinaro L, Ma L, Alvarado D, Ambrogio C, Voena C, Blasco R, Li T, Klein D, Irvine D, Papotti M, Savoldo B, Dotti G, Chiarle R. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 2023, 41: 2100-2116.e10. PMID: 38039964, PMCID: PMC10793157, DOI: 10.1016/j.ccell.2023.11.004.Peer-Reviewed Original ResearchConceptsALK inhibitorsALK expressionChimeric antigen receptor TBest tumor antigensPromising clinical activityExpression of ALKMost normal tissuesHematologic malignanciesClinical activityMost neuroblastomasAnaplastic lymphoma kinase (ALK) receptorTherapeutic successTumor antigensPotent efficacySolid tumorsTherapeutic efficacyNeuroblastomaTumor growthOncogenic driversNeuroblastoma cellsNormal tissuesALKKinase receptorsMonotherapyInhibitors
2022
317 ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density
Bergaggio E, Tai W, Aroldi A, Landoni E, Nuesch M, Mota I, Metovic J, Ma L, Alvarado D, Ambrogio C, Voena C, Blasco R, Li T, Klein D, Irvine D, Papotti M, Savoldo B, Dotti G, Chiarle R. 317 ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density. 2022, a333-a333. DOI: 10.1136/jitc-2022-sitc2022.0317.Peer-Reviewed Original ResearchMonospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
Peng L, Hu Y, Mankowski MC, Ren P, Chen RE, Wei J, Zhao M, Li T, Tripler T, Ye L, Chow RD, Fang Z, Wu C, Dong MB, Cook M, Wang G, Clark P, Nelson B, Klein D, Sutton R, Diamond MS, Wilen CB, Xiong Y, Chen S. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Nature Communications 2022, 13: 1638. PMID: 35347138, PMCID: PMC8960874, DOI: 10.1038/s41467-022-29288-3.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Authentic SARS-CoV-2Effective therapeutic optionPotent SARS-CoV-2SARS-CoV-2 variantsVariants of concernRepertoire of therapeuticsBreakthrough infectionsTherapeutic optionsMultiple vaccinesPathogen SARS-CoV-2Delta variantB cellsPotent efficacyHumanized antibodyDistinct epitopesBispecific antibodiesOriginal virusSpike receptorStrong inhibitory activityMonoclonal antibodiesAntibodiesStrong potencyLead clonesLead antibodies
2021
Structural basis for ligand reception by anaplastic lymphoma kinase
Li T, Stayrook SE, Tsutsui Y, Zhang J, Wang Y, Li H, Proffitt A, Krimmer SG, Ahmed M, Belliveau O, Walker IX, Mudumbi KC, Suzuki Y, Lax I, Alvarado D, Lemmon MA, Schlessinger J, Klein DE. Structural basis for ligand reception by anaplastic lymphoma kinase. Nature 2021, 600: 148-152. PMID: 34819665, PMCID: PMC8639777, DOI: 10.1038/s41586-021-04141-7.Peer-Reviewed Original Research
2019
H2A.Z facilitates licensing and activation of early replication origins
Long H, Zhang L, Lv M, Wen Z, Zhang W, Chen X, Zhang P, Li T, Chang L, Jin C, Wu G, Wang X, Yang F, Pei J, Chen P, Margueron R, Deng H, Zhu M, Li G. H2A.Z facilitates licensing and activation of early replication origins. Nature 2019, 577: 576-581. PMID: 31875854, DOI: 10.1038/s41586-019-1877-9.Peer-Reviewed Original ResearchConceptsOrigin recognition complexHistone variant H2A.ZEarly replication originsReplication originsVariant H2A.ZReplication timingChromatin-based regulatory mechanismsEarly replication timingGenome-wide studiesNascent DNA strandsH2A.Z resultsNucleosome bindsDNA replicationH2A.ZHistone H4Cell cycle1Precise duplicationRegulated processDNA sequencesRegulatory mechanismsHeLa cellsDNA strandsORC1Firing efficiencyGenome
2016
Novel Inhibitors of Toxin HipA Reduce Multidrug Tolerant Persisters
Li T, Yin N, Liu H, Pei J, Lai L. Novel Inhibitors of Toxin HipA Reduce Multidrug Tolerant Persisters. ACS Medicinal Chemistry Letters 2016, 7: 449-453. PMID: 27190591, PMCID: PMC4867474, DOI: 10.1021/acsmedchemlett.5b00420.Peer-Reviewed Original ResearchLife-threatening infectious diseaseDrug-tolerant bacteriaAntibiotic therapyNovel inhibitorsInhibition of toxinMultidrug-tolerant persistersFirst toxinInfectious diseasesEscherichia coli persistenceBacterial persistencePotent oneInhibitorsTolerant persistersPersister fractionToxinToxin-antitoxin modulesTherapyPersistersDisease
2013
Discovery of novel chemoeffectors and rational design of Escherichia coli chemoreceptor specificity
Bi S, Yu D, Si G, Luo C, Li T, Ouyang Q, Jakovljevic V, Sourjik V, Tu Y, Lai L. Discovery of novel chemoeffectors and rational design of Escherichia coli chemoreceptor specificity. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 16814-16819. PMID: 24082101, PMCID: PMC3801017, DOI: 10.1073/pnas.1306811110.Peer-Reviewed Original ResearchConceptsKey interactionsSite-specific mutationsBasic amino acidsMain chain carbonylBacterial chemoreceptorsChemoreceptor TarNonnative ligandsΑ4 helixKey residuesDownstream signalingDiverse stimuliChemotaxis signalingLarge compound librariesMolecular insightsAttractant responseAmino acidsFunctional regionsRegion IChemoeffectorsVivo approachesBinding patternSignalingCompound librariesChemotactic responseAttractants
Links & Media
News
- March 30, 2022
The Growth of the Cancer Biology Institute